Search

Your search keyword '"Rouvière O"' showing total 290 results
Start Over Author "Rouvière O" Publication Year Range Last 10 years
290 results on '"Rouvière O"'

7. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H.M., De Reijke, T.M., De Santis, M., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M.J., Shariat, S.F., Van Der Kwast, T., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P.C., Bochner, B.H., Bolla, M., Boormans, J.L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., De Bari, B., DeBlok, W., De Visschere, P.J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J.L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J.J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D.E., Hartmann, A., Hayne, D., Henry, A.M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B.A., Jones, R., Kamat, A.M., Khoo, V., Kiltie, A.E., Krege, S., Ladoire, S., Lara, P.C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Carmen Mir, M., Moschini, M., Mostafid, H., Müller, A.-C., Müller, C.R., N’Dow, J., Necchi, A., Neuzillet, Y., Oddens, J.R., Oldenburg, J., Osanto, S., Oyen, W.J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M.I., Pieters, B.R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J.E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R.J., Smits, A., Stenzl, A., Thalmann, G.N., Tombal, B., Turkbey, B., Vahr Lauridsen, S., Valdagni, R., Van Der Heijden, A.G., Van Poppel, H., Vartolomei, M.D., Veskimäe, E., Vilaseca, A., Vives Rivera, F.A., Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., and Witjes, J.A.

Published
2019
Full Text
View/download PDF

9. Five simultaneous artificial intelligence data challenges on ultrasound, CT, and MRI

Author

Lassau, N., Estienne, T., de Vomecourt, P., Azoulay, M., Cagnol, J., Garcia, G., Majer, M., Jehanno, E., Renard-Penna, R., Balleyguier, C., Bidault, F., Caramella, C., Jacques, T., Dubrulle, F., Behr, J., Poussange, N., Bocquet, J., Montagne, S., Cornelis, F., Faruch, M., Bresson, B., Brunelle, S., Jalaguier-Coudray, A., Amoretti, N., Blum, A., Paisant, A., Herreros, V., Rouviere, O., Si-Mohamed, S., Di Marco, L., Hauger, O., Garetier, M., Pigneur, F., Bergère, A., Cyteval, C., Fournier, L., Malhaire, C., Drape, J.-L., Poncelet, E., Bordonne, C., Cauliez, H., Budzik, J.-F., Boisserie, M., Willaume, T., Molière, S., Peyron Faure, N., Caius Giurca, S., Juhan, V., Caramella, T., Perrey, A., Desmots, F., Faivre-Pierre, M., Abitbol, M., Lotte, R., Istrati, D., Guenoun, D., Luciani, A., Zins, M., Meder, J.-F., and Cotten, A.

Published
2019
Full Text
View/download PDF

12. Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence: A Post Hoc Analysis the DENERHTN Study

Author

Hamdidouche, Idir, Gosse, Philippe, Cremer, Antoine, Lorthioir, Aurelien, Delsart, Pascal, Courand, Pierre-Yves, Denolle, Thierry, Halimi, Jean-Michel, Girerd, Xavier, Ormezzano, Olivier, Rossignol, Patrick, Pereira, Helena, Azizi, Michel, Amar, L, Bobrie, G, Monge, M, Pagny, JY, Sapoval, M, Claisse, G, Midulla, M, Mounier-Vehier, C, Dauphin, R, Fauvel, JP, Lantelme, P, Rouvière, O, Grenier, N, Lebras, Y, Trillaud, H, Dourmap, C, Heautot, JF, Larralde, A, Paillard, F, Cluzel, P, Rosenbaum, D, Alison, D, Popovic, B, Zannad, F, Baguet, JP, Thony, F, Bartoli, JM, Vaïsse, B, Drouineau, J, Herpin, D, Sosner, P, Tasu, JP, Velasco, S, Ribstein, J, Kovacsik, H, Bouhanick, B, Chamontin, B, Rousseau, H, Le Jeune, S, Lopez-Sublet, M, Mourad, JJ, Bellmann, L, Esnault, V, Ferrari, E, and Chatellier, G.

Published
2019
Full Text
View/download PDF

19. A systematic review of the efficacy and toxicity of brachytherapy boost combined with external beam radiotherapy for nonmetastatic prostate cancer

Author

Tilki, Derya, Slevin, F.; Zattoni, F.; Checcucci, E.; Cumberbatch, M.G.K.; Nacchia, A.; Cornford, P.; Briers, E.; De Meerleer, G.; De Santis, M.; Eberli, D.; Gandaglia, G.; Gillessen, S.; Grivas, N.; Liew, M.; Linares Espinós, E.E.; Oldenburg, J.; Oprea-Lager, D.E.; Ploussard, G.; Rouvière, O.; Schoots, I.G.; Smith, E.J.; Stranne, J.; Smith, C.T.; Van Den Bergh, R.C.N.; Van Oort, I.M.; Wiegel, T.; Yuan, C.Y.; Van den Broeck, T.; Henry, A.M., Koç University Hospital, School of Medicine, Tilki, Derya, Slevin, F.; Zattoni, F.; Checcucci, E.; Cumberbatch, M.G.K.; Nacchia, A.; Cornford, P.; Briers, E.; De Meerleer, G.; De Santis, M.; Eberli, D.; Gandaglia, G.; Gillessen, S.; Grivas, N.; Liew, M.; Linares Espinós, E.E.; Oldenburg, J.; Oprea-Lager, D.E.; Ploussard, G.; Rouvière, O.; Schoots, I.G.; Smith, E.J.; Stranne, J.; Smith, C.T.; Van Den Bergh, R.C.N.; Van Oort, I.M.; Wiegel, T.; Yuan, C.Y.; Van den Broeck, T.; Henry, A.M., Koç University Hospital, and School of Medicine

Abstract

Background Central nervous system (CNS) prophylactic options for diffuse large B-cell lymphoma (DLBCL) are administered differently in most centers. Unfortunately, there is still not a consensus on which patients, which regimen, for how many cycles, and when prophy-laxis should be administered. Thus, this remains an unmet clinical need. Methods We administered a survey study under the Lymphoma Scientific Subcommittee of the Turkish Society of Haematology. The questions were directed to hematologists through the monkey survey system. Results The CNS International Prognostic Index score is a factor that clinicians frequently use when deciding on prophylaxis and is considered reliable. Although the perspective on anatomical risk factors is similar to that reported in the literature, breast involvement is still considered a critical risk factor in Turkey. Participants considered double or triple hit and double/triple expressor lymphoma as significant risk factors. Various methods have been used to demonstrate CNS relapses. Intrathecal prophylaxis is the preferred method. Conclusion There are diverse methodological and technical ideas. The controversial results reported in the literature on the effectiveness of CNS prophylaxis may explain this finding. Although CNS prophylactic methods for patients with DLBCL are still controversial, the effect of secondary CNS involvement on survival is inevitable. Standard practices followed by na-tional guidelines may be effective in reducing the variety of application methods and creat-ing homogeneous results for efficacy and survival follow-up studies., NA

Published
2023

20. Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review.

Author

Marra, G., Leenders, G.J.L.H. van, Zattoni, F., Kesch, C., Rajwa, P., Cornford, P., Kwast, T. van der, Bergh, R.C.N. van den, Briers, E., Broeck, T. Van den, Meerleer, G. de, Santis, M. de, Eberli, D., Farolfi, A., Gillessen, S., Grivas, N., Grummet, J.P., Henry, A.M., Lardas, M., Lieuw, M., Linares Espinós, E., Mason, M.D., O'Hanlon, S., Oort, I.M. van, Oprea-Lager, D.E., Ploussard, G., Rouvière, O., Schoots, I.G., Stranne, J., Tilki, D., Wiegel, T., Willemse, P.M., Mottet, N., Gandaglia, G., Marra, G., Leenders, G.J.L.H. van, Zattoni, F., Kesch, C., Rajwa, P., Cornford, P., Kwast, T. van der, Bergh, R.C.N. van den, Briers, E., Broeck, T. Van den, Meerleer, G. de, Santis, M. de, Eberli, D., Farolfi, A., Gillessen, S., Grivas, N., Grummet, J.P., Henry, A.M., Lardas, M., Lieuw, M., Linares Espinós, E., Mason, M.D., O'Hanlon, S., Oort, I.M. van, Oprea-Lager, D.E., Ploussard, G., Rouvière, O., Schoots, I.G., Stranne, J., Tilki, D., Wiegel, T., Willemse, P.M., Mottet, N., and Gandaglia, G.

Abstract

01 juli 2023, Item does not contain fulltext, CONTEXT: The optimal management for men with prostate cancer (PCa) with unconventional histology (UH) is unknown. The outcome for these cancers might be worse than for conventional PCa and so different approaches may be needed. OBJECTIVE: To compare oncological outcomes for conventional and UH PCa in men with localized disease treated with curative intent. EVIDENCE ACQUISITION: A systematic review adhering to the Referred Reporting Items for Systematic Reviews and Meta-Analyses was prospectively registered on PROSPERO (CRD42022296013) was performed in July 2021. EVIDENCE SYNTHESIS: We screened 3651 manuscripts and identified 46 eligible studies (reporting on 1 871 814 men with conventional PCa and 6929 men with 10 different PCa UHs). Extraprostatic extension and lymph node metastases, but not positive margin rates, were more common with UH PCa than with conventional tumors. PCa cases with cribriform pattern, intraductal carcinoma, or ductal adenocarcinoma had higher rates of biochemical recurrence and metastases after radical prostatectomy than for conventional PCa cases. Lower cancer-specific survival rates were observed for mixed cribriform/intraductal and cribriform PCa. By contrast, pathological findings and oncological outcomes for mucinous and prostatic intraepithelial neoplasia (PIN)-like PCa were similar to those for conventional PCa. Limitations of this review include low-quality studies, a risk of reporting bias, and a scarcity of studies that included radiotherapy. CONCLUSIONS: Intraductal, cribriform, and ductal UHs may have worse oncological outcomes than for conventional and mucinous or PIN-like PCa. Alternative treatment approaches need to be evaluated in men with these cancers. PATIENT SUMMARY: We reviewed the literature to explore whether prostate cancers with unconventional growth patterns behave differently to conventional prostate cancers. We found that some unconventional growth patterns have worse outcomes, so we need to investigate if they nee

Published
2023

22. Modern Imaging in Prostate Cancer: Do We Treat Patients, or Their Scans?

Author

Mason, M. D., van der Kwast, T. H., Mottet, N., Oprea-Lager, D. E., Rouvière, O., Radiology and nuclear medicine, CCA - Imaging and biomarkers, and Pathology

Subjects
Male, SDG 3 - Good Health and Well-being, Urology, Humans, Prostatic Neoplasms, Neoplasm Staging
Abstract

New imaging techniques are more sensitive in prostate cancer and reveal sites of disease that may never have been seen with conventional imaging, resulting in stage migration and potentially a change in the clinical management. Until long-term data provide a better understanding of the natural history of the disease defined by more sensitive imaging, patients and clinicians should recognise the considerable uncertainty about whether these improve outcomes. It is hoped that the next iteration of the TNM classification will recognise the problem in some way.

Published
2022
Full Text
View/download PDF

29. Evaluation of oncological outcomes and data quality in studies assessing nerve sparing versus non-nerve sparing radical prostatectomy in non-metastatic prostate cancer: A systematic review

Author

Moris, L., primary, Gandaglia, G., additional, Vilaseca, A., additional, Van Den Broeck, T., additional, Briers, E., additional, De Santis, M., additional, Gillessen, S., additional, Grivas, N., additional, Henry, A., additional, Lam, T.B., additional, Lardas, M., additional, Mason, M., additional, Oprea-Lager, D., additional, Ploussard, G., additional, Rouvière, O., additional, Schoots, I.G., additional, Van Der Poel, H., additional, Wiegel, T., additional, Willemse, P-P., additional, Grummet, J.P., additional, Tilke, D., additional, Van Den Bergh, R.C.N., additional, Cornford, P., additional, and Mottet, N., additional

Published
2021
Full Text
View/download PDF

30. A systematic review on the impact of surgeon and hospital caseload volume on oncological and non-oncological outcomes after radical prostatectomy for non-metastatic prostate cancer

Author

Van Den Broeck, T., primary, Oprea-Lager, D., additional, Moris, L., additional, Kailavasan, M., additional, Briers, E., additional, Cornford, P., additional, De Santis, M., additional, Gandaglia, G., additional, Gillessen Sommer, S., additional, Grummet, J.P., additional, Grivas, N., additional, Lam, T.B., additional, Lardas, M., additional, Liew, M., additional, Mason, M., additional, O’Hanlon, S., additional, Ploussard, G., additional, Rouvière, O., additional, Schoots, I., additional, Tilki, D., additional, Van Den Bergh, R.C.N., additional, Van Der Poel, H., additional, Wiegel, T., additional, Willemse, P., additional, and Mottet, N., additional

Published
2021
Full Text
View/download PDF

33. PT348 - Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: A systematic review

Author

Van Den Broeck, T., Van Den Bergh, R.C.N., Arfi, N., Gross, T., Moris, L., Briers, E., Cumberbatch, M.G.K., De Santis, M., Tilki, D., Fanti, S., Fossati, N., Gillessen Sommer, S., Grummet, J., Henry, A., Lardas, M., Liew, M., Rouvière, O., Pecanka, J., Mason, M., Schoots, I.G., Van der Kwast, T., Van Der Poel, H.G., Wiegel, T., Willemse, P-P.M., Yuan, Y., Lam, T.B., Cornford, P., and Mottet, N.

Published
2019
Full Text
View/download PDF

35. The EAU biochemical recurrence risk stratification after radical prostatectomy

Author

Van Den Broeck, T., primary, Van Den Bergh, R.C.N., additional, Arfi, N., additional, Gross, T., additional, Moris, L., additional, Briers, E., additional, Markus, C., additional, Maria, D.S., additional, Fanti, S., additional, Fossati, N., additional, Gillessen, S., additional, Grummet, J.P., additional, Henry, A.M., additional, Lardas, M., additional, Rouvière, O., additional, Mason, M.D., additional, Schoots, I., additional, Van Der Kwast, T., additional, Van Der Poel, H.G., additional, Wiegel, T., additional, Willemse, P.M., additional, Lam, T.B., additional, Cornford, P., additional, Mottet, N., additional, and Tilki, D., additional

Published
2020
Full Text
View/download PDF

36. EAU PCa Guideline Panel: Systematic review of focal ablative therapy for localised prostate cancer compared with standard therapies

Author

Bates, A., primary, Lumsden, T.L, additional, Ayres, J., additional, Schoots, I., additional, Willemse, P., additional, Yuan, C., additional, Van Den Bergh, R., additional, Grummet, J., additional, Van Der Poel, H., additional, Rouvière, O., additional, Lam, T., additional, Cornford, P., additional, and Mottet, N., additional

Published
2020
Full Text
View/download PDF

37. Current treatment options for locally advanced prostate cancer: EAU (-SIOG) guidelines view and recommendations

Author

Moris, L., primary, Cumberbatch, M.C., additional, Van Den Broeck, T., additional, Gandaglia, G., additional, Fossati, N., additional, Briers, E., additional, Cornford, P., additional, De Santis, M., additional, Fanti, S., additional, Gillessen, S., additional, Grummet, J., additional, Henry, A.M., additional, Lam, T.B.L., additional, Lardas, M., additional, Liew, M., additional, Mason, M.D., additional, Rouvière, O., additional, Tilki, D., additional, Schoots, I.G., additional, Van Den Bergh, R.C.N., additional, Van Der Kwast, T.H., additional, Van Der Poel, H.G, additional, Willemse, P.M., additional, Mottet, N., additional, and Wiegel, T., additional

Published
2020
Full Text
View/download PDF

38. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

Author

Witjes, J.A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. De Blok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Mir, M.C. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Lauridsen, S.V. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Rivera, F.A.V. Wiegel, T. Wiklund, P. Willemse, P.-P.M. Williams, A. Zigeuner, R. Horwich, A.

Abstract

The authors regret that a co-author was mistakenly missed from the authorship. The following co-author should have been included in the authorship: Peter-Paul M. Willemse Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands © 2019 European Society of Medical Oncology and European Association of Urology

Published
2020

39. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.

Subjects
Consensus, Follow-up, education, Bladder cancer, Diagnosis, Treatment, Delphi
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

40. Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.016: Prebiopsy MRI: Through the Looking Glass

Author

Bergh, R.C.N. (Roderick) van den, Rouvière, O. (Olivier), Kwast, Th.H. (Theo) van der, Briers, E. (Erik), van den Broeck, T. (Thomas), Cornford, P. (Philip), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fanti, S. (Stefano), Fossati, N. (Nicola), Gandaglia, G. (Giorgio), Grivas, N. (Nikolaos), Grummet, J. (Jeremy), Lam, T.B. (Thomas B.), Lardas, M. (Michael), Liew, M. (Matthew), Moris, L. (Lisa), Mason, M.D. (Malcolm), Mottet, N. (Nicolas), Oprea-Lager, D.E. (Daniela E.), Ploussard, G. (Guillaume), Schoots, I.G. (Ivo), Tilki, D. (Derya), Poel, H.G. (Henk) van der, Wiegel, T. (Thomas), Willemse, P.-P.M. (Peter-Paul M.), Bergh, R.C.N. (Roderick) van den, Rouvière, O. (Olivier), Kwast, Th.H. (Theo) van der, Briers, E. (Erik), van den Broeck, T. (Thomas), Cornford, P. (Philip), Cumberbatch, M.G. (Marcus G.), Santis, M. (Maria) de, Fanti, S. (Stefano), Fossati, N. (Nicola), Gandaglia, G. (Giorgio), Grivas, N. (Nikolaos), Grummet, J. (Jeremy), Lam, T.B. (Thomas B.), Lardas, M. (Michael), Liew, M. (Matthew), Moris, L. (Lisa), Mason, M.D. (Malcolm), Mottet, N. (Nicolas), Oprea-Lager, D.E. (Daniela E.), Ploussard, G. (Guillaume), Schoots, I.G. (Ivo), Tilki, D. (Derya), Poel, H.G. (Henk) van der, Wiegel, T. (Thomas), and Willemse, P.-P.M. (Peter-Paul M.)

Published
2020
Full Text
View/download PDF

41. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training

Author

Rooij, M. (Maarten) de, Israël, B. (Bas), Tummers, M. (Marcia), Ahmed, H.U. (Hashim), Barrett, T. (Tristan), Giganti, F. (Francesco), Hamm, B. (Bernd), Løgager, V. (Vibeke), Padhani, A. (Anwar), Panebianco, V. (Valeria), Puech, P. (Philippe), Richenberg, J. (Jonathan), Rouvière, O. (Olivier), Salomon, G. (Georg), Schoots, I.G. (Ivo), Veltman, J., Villeirs, G. (Geert), Walz, J. (Jochen), Barentsz, J. (Jelle), Rooij, M. (Maarten) de, Israël, B. (Bas), Tummers, M. (Marcia), Ahmed, H.U. (Hashim), Barrett, T. (Tristan), Giganti, F. (Francesco), Hamm, B. (Bernd), Løgager, V. (Vibeke), Padhani, A. (Anwar), Panebianco, V. (Valeria), Puech, P. (Philippe), Richenberg, J. (Jonathan), Rouvière, O. (Olivier), Salomon, G. (Georg), Schoots, I.G. (Ivo), Veltman, J., Villeirs, G. (Geert), Walz, J. (Jochen), and Barentsz, J. (Jelle)

Abstract

Objectives: This study aims to define consensus-based criteria for acquiring and reporting prostate MRI and establishing prerequisites for image quality. Methods: A total of 44 leading urologists and urogenital radiologists who are experts in prostate cancer imaging from the European Society of Urogenital Radiology (ESUR) and EAU Section of Urologic Imaging (ESUI) participated in a Delphi consensus process. Panellists completed two rounds of questionnaires with 55 items under three headings: image quality assessment, interpretation and reporting, and radiologists’ experience plus training centres. Of 55 questions, 31 were rated for agreement on a 9-point scale, and 24 were multiple-choice or open. For agreement items, there was consensus agreement with an agreement ≥ 70% (score 7–9) and disag

Published
2020
Full Text
View/download PDF

42. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training

Author

de Rooij, M, Israël, B, Tummers, M, Ahmed, HU, Barrett, T, Giganti, F, Hamm, B, Løgager, V, Padhani, A, Panebianco, V, Puech, P, Richenberg, J, Rouvière, O, Salomon, G, Schoots, Ivo, Veltman, J, Villeirs, G, Walz, J, Barentsz, JO, de Rooij, M, Israël, B, Tummers, M, Ahmed, HU, Barrett, T, Giganti, F, Hamm, B, Løgager, V, Padhani, A, Panebianco, V, Puech, P, Richenberg, J, Rouvière, O, Salomon, G, Schoots, Ivo, Veltman, J, Villeirs, G, Walz, J, and Barentsz, JO

Published
2020

45. Kindey Cortex Segmentation in 2D CT with U-Nets Ensemble Aggregation

Author

Couteaux, Vincent, Si-Mohamed, S., Renard-Penna, R., Nempont, O., Lefevre, T., Popoff, A., Pizaine, Guillaume, Villain, N., Bloch, Isabelle, Behr, J., Bellin, M.-F., Roy, C., Rouvière, O., Montagne, S., Lassau, N., Boussel, L., Image, Modélisation, Analyse, GEométrie, Synthèse (IMAGES), Laboratoire Traitement et Communication de l'Information (LTCI), Institut Mines-Télécom [Paris] (IMT)-Télécom Paris-Institut Mines-Télécom [Paris] (IMT)-Télécom Paris, Département Images, Données, Signal (IDS), and Télécom ParisTech

Subjects
[INFO.INFO-LG]Computer Science [cs]/Machine Learning [cs.LG], [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

46. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. DeBlok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Carmen Mir, M. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Vahr Lauridsen, S. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Vives Rivera, F.A. Wiegel, T. Wiklund, P. Williams, A. Zigeuner, R. Witjes, J.A.

Subjects
education
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. © 2019 European Society for Medical Oncology

Published
2019

49. Mesure des concentrations intracellulaires de phosphate inorganique et d’ATP par Spectroscopie par Résonance Magnétique pendant une séance d’hémodialyse chez l’insuffisant rénal chronique terminal (Etude CIPHEMO)

Author

Chazot, G., Lemoine, S., Kocevar, G., Kalbacher, Elsa, Varennes, Annie, Carlier, M.C., Normand, G., Sappey-Marinier, Dominique, Rouvière, O., Juilard, L., RMN et optique : De la mesure au biomarqueur, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Edouard Herriot [CHU - HCL], and Hospices Civils de Lyon (HCL)

Subjects
[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results